01 October 2025
01 October 2025
Healthcare funding exclusions emerged as a key sticking point for the mainly Democratic senators who opposed the Republicans’ H.R. 5371 funding bill.
Pfizer becomes the first company to reach an agreement with the US government on MFN pricing.
Changing trends in the biopharma sector may mean new risks for established players and opportunities for growth, says BIA chief.
Turn Biotechnologies is focused on induced pluripotent stem cells and cellular reprogramming.
The capital infusion is earmarked for the progression of monoclonal antibody, VGA039.
‘NewCo’ licensing of clinical candidates is allowing Chinese biotechs to offload costs while expanding profits on a global scale.
At the 2025 European Respiratory Society (ERS) International Congress taking place in Amsterdam, the Netherlands, from 27 September to 1 October, researchers from Canada's Dalhousie University and the University of Toronto have presented findings from a comprehensive registry-based analysis examining the long-term clinical and microbiological impacts of cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy in cystic fibrosis (CF) patients.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
